" class="no-js "lang="en-US"> Peter Zerhouni - Medtech Alert
Thursday, November 07, 2024
Peter Zerhouni

Peter Zerhouni

About Peter Zerhouni

Zerhouni has extensive experience in developing life science companies from both a scientific and commercial perspective. Peter joined InDex from the listed company Diamyd Medical AB where he was CEO since 2011 and where he also has been head of business development. He was a driving force behind one of the largest biotech out-licensing deals in Sweden in 2010. Zerhouni has previously held various positions at ING Bank in Brussels and Amsterdam. He holds a Master of Science degree in Biology as well as a Bachelor of Science degree in Business Administration and Economics from Lund University (part of the course work was completed at University of California at Berkeley).

Shareholding in InDex: Direct holding of 660 000 shares and 333 333 warrants (LTIP 2020) and 1 930 700 employee stock options (LTIP 2021).

Related Story

Index Pharmaceuticals Prepares for Commercialisation of Cobitolimod

March 14 2022

InDex Pharmaceuticals Holding AB (publ)is planning for self-commercialisation of the drug candidate cobitolimod in the […]